Weiss, S. & Bogen, B. MHC class II-restricted presentation of intracellular antigen. Cell 64, 767–776 (1991).
Axelrod, M. L., Cook, R. S., Johnson, D. B. & Balko, J. M. Biological consequences of MHC-II expression by tumor cells in cancer. Clin. Cancer Res. 25, 2392–2402 (2019).
Nanaware, P. P., Cruz, J., Khaja, M., Shaffer, S. A. & Stern, L. Inhibited MHC class I and MHC class II antigen processing and presentation upon SARS-CoV-2 infection. J. Immunol. 210, 222.02 (2023).
Gras, S. CD4+ T cell mediated HLA class II cross-restriction in HIV controllers. J. Immunol. 204, eaat0687 (2020).
Zakharova, M. Y., Belyanina, T. A., Sokolov, A. V., Kiselev, I. S. & Mamedov, A. E. The contribution of major histocompatibility complex class II genes to an association with autoimmune diseases. Acta Naturae 11, 4–12 (2019).
Wieber, K., Zimmer, C. L. & Hertl, M. Detection of autoreactive CD4+ T cells by MHC class II multimers in HLA-linked human autoimmune diseases. J. Clin. Invest. 131, e148674 (2021).
Davies, C. S. et al. Immunogenetic variation shapes the gut microbiome in a natural vertebrate population. Microbiome 10, 41 (2022).
Wosen, J. E., Mukhopadhyay, D., Macaubas, C. & Mellins, E. D. Epithelial MHC class II expression and its role in antigen presentation in the gastrointestinal and respiratory tracts. Front. Immunol. 9, 2144 (2018).
Roche, P. A. & Furuta, K. The ins and outs of MHC class II-mediated antigen processing and presentation. Nat. Rev. Immunol. 15, 203–216 (2015).
Pishesha, N., Harmand, T. J. & Ploegh, H. L. A guide to antigen processing and presentation. Nat. Rev. Immunol. 22, 751–764 (2022).
Stern, L. J. & Santambrogio, L. The melting pot of the MHC II peptidome. Curr. Opin. Immunol. 40, 70–77 (2016).
Baulu, E., Gardet, C., Chuvin, N. & Depil, S. TCR-engineered T cell therapy in solid tumors: state of the art and perspectives. Sci. Adv. 9, eadf3700 (2023).
Weber, K. S., Donermeyer, D. L., Allen, P. M. & Kranz, D. M. Class II-restricted T cell receptor engineered in vitro for higher affinity retains peptide specificity and function. Proc. Natl Acad. Sci. USA 102, 19033–19038 (2005).
Li, Y., Jiang, W. & Mellins, E. D. TCR-like antibodies targeting autoantigen–MHC complexes: a mini-review. Front. Immunol. 13, 968432 (2022).
Poncette, L., Chen, X., Lorenz, F. K. & Blankenstein, T. Effective NY-ESO-1-specific MHC II-restricted T cell receptors from antigen-negative hosts enhance tumor regression. J. Clin. Invest. 129, 324–335 (2019).
Spanier, J. A. et al. Tregs with an MHC class II peptide-specific chimeric antigen receptor prevent autoimmune diabetes in mice. J. Clin. Invest. 133, e168601 (2023).
Hoydahl, L. S., Frick, R., Sandlie, I. & Loset, G. A. Targeting the MHC ligandome by use of TCR-like antibodies. Antibodies 8, 32 (2019).
Wucherpfennig, K. W. & Strominger, J. L. Molecular mimicry in T cell-mediated autoimmunity: viral peptides activate human T cell clones specific for myelin basic protein. Cell 80, 695–705 (1995).
Lunemann, J. D. et al. EBNA1-specific T cells from patients with multiple sclerosis cross react with myelin antigens and co-produce IFN-γ and IL-2. J. Exp. Med. 205, 1763–1773 (2008).
Jardetzky, T. S. et al. Crystallographic analysis of endogenous peptides associated with HLA-DR1 suggests a common, polyproline II-like conformation for bound peptides. Proc. Natl Acad. Sci. USA 93, 734–738 (1996).
Hahn, M., Nicholson, M. J., Pyrdol, J. & Wucherpfennig, K. W. Unconventional topology of self peptide–major histocompatibility complex binding by a human autoimmune T cell receptor. Nat. Immunol. 6, 490–496 (2005).
Beringer, D. X. et al. T cell receptor reversed polarity recognition of a self-antigen major histocompatibility complex. Nat. Immunol. 16, 1153–1161 (2015).
Cole, D. K. et al. Human TCR-binding affinity is governed by MHC class restriction. J. Immunol. 178, 5727–5734 (2007).
Hennecke, J., Carfi, A. & Wiley, D. C. Structure of a covalently stabilized complex of a human αβ T-cell receptor, influenza HA peptide and MHC class II molecule, HLA-DR1. EMBO J. 19, 5611–5624 (2000).
Hennecke, J. & Wiley, D. C. Structure of a complex of the human α/β T cell receptor (TCR) HA1.7, influenza hemagglutinin peptide, and major histocompatibility complex class II molecule, HLA-DR4 (DRA*0101 and DRB1*0401): insight into TCR cross-restriction and alloreactivity. J. Exp. Med. 195, 571–581 (2002).
Broughton, S. E. et al. Biased T cell receptor usage directed against human leukocyte antigen DQ8-restricted gliadin peptides is associated with celiac disease. Immunity 37, 611–621 (2012).
Frick, R. et al. A high-affinity human TCR-like antibody detects celiac disease gluten peptide–MHC complexes and inhibits T cell activation. Sci. Immunol. 6, eabg4925 (2021).
Hülsmeyer, M. et al. A major histocompatibility complex–peptide-restricted antibody and T cell receptor molecules recognize their target by distinct binding modes: crystal structure of human leukocyte antigen (HLA)-A1–MAGE-A1 in complex with Fab-Hyb3. J. Biol. Chem. 280, 2972–2980 (2005).
Ataie, N. et al. Structure of a TCR-mimic antibody with target predicts pharmacogenetics. J. Mol. Biol. 428, 194–205 (2016).
Starwalt, S. E., Masteller, E. L., Bluestone, J. A. & Kranz, D. M. Directed evolution of a single-chain class II MHC product by yeast display. Protein Eng. 16, 147–156 (2003).
Dahan, R. & Reiter, Y. T-cell-receptor-like antibodies—generation, function and applications. Expert Rev. Mol. Med. 14, e6 (2012).
Cao, L. X. et al. Design of protein-binding proteins from the target structure alone. Nature 605, 551–560 (2022).
Watson, J. L. et al. De novo design of protein structure and function with RFdiffusion. Nature 620, 1089–1100 (2023).
Wang, L. et al. Crystal structure of a complete ternary complex of TCR, superantigen and peptide–MHC. Nat. Struct. Mol. Biol. 14, 169–171 (2007).
Deacy, A. M., Gan, S. K. & Derrick, J. P. Superantigen recognition and interactions: functions, mechanisms and applications. Front. Immunol. 12, 731845 (2021).
Hodtsev, A. S., Choi, Y. W., Spanopoulou, E. & Posnett, D. N. Mycoplasma superantigen is a CDR3-dependent ligand for the T cell antigen receptor. J. Exp. Med. 187, 319–327 (1998).
Huang, P. S. et al. RosettaRemodel: a generalized framework for flexible backbone protein design. PLoS ONE 6, e24109 (2011).
Wintjens, R. T., Rooman, M. J. & Wodak, S. J. Automatic classification and analysis of αα-turn motifs in proteins. J. Mol. Biol. 255, 235–253 (1996).
Mandic, M. et al. One NY-ESO-1-derived epitope that promiscuously binds to multiple HLA-DR and HLA-DP4 molecules and stimulates autologous CD4+ T cells from patients with NY-ESO-1-expressing melanoma. J. Immunol. 174, 1751–1759 (2005).
Liu, R., Jiang, W. & Mellins, E. D. Yeast display of MHC-II enables rapid identification of peptide ligands from protein antigens (RIPPA). Cell Mol. Immunol. 18, 1847–1860 (2021).
Jiang, W. & Boder, E. T. High-throughput engineering and analysis of peptide binding to class II MHC. Proc. Natl Acad. Sci. USA 107, 13258–13263 (2010).
Kowalsky, C. A. et al. Rapid fine conformational epitope mapping using comprehensive mutagenesis and deep sequencing. J. Biol. Chem. 290, 26457–26470 (2015).
Kowalsky, C. A. et al. High-resolution sequence-function mapping of full-length proteins. PLoS ONE 10, e0118193 (2015).
Holland, C. J., Cole, D. K. & Godkin, A. Re-directing CD4 T cell responses with the flanking residues of MHC class II-bound peptides: the core is not enough. Front. Immunol. 4, 172 (2013).
Mellins, E. D. & Stern, L. J. HLA-DM and HLA-DO, key regulators of MHC-II processing and presentation. Curr. Opin. Immunol. 26, 115–122 (2014).
Abualrous, E. T. et al. MHC-II dynamics are maintained in HLA-DR allotypes to ensure catalyzed peptide exchange. Nat. Chem. Biol. 19, 1196–1204 (2023).
Denzin, L. K., Robbins, N. F., Carboynewcomb, C. & Cresswell, P. Assembly and intracellular transport of HLA-DM and correction of the class II antigen-processing defect in T2 cells. Immunity 1, 595–606 (1994).
Abualrous, E. T., Sticht, J. & Freund, C. Major histocompatibility complex (MHC) class I and class II proteins: impact of polymorphism on antigen presentation. Curr. Opin. Immunol. 70, 95–104 (2021).
Ghosh, P., Amaya, M., Mellins, E. & Wiley, D. C. The structure of an intermediate in class II MHC maturation: CLIP bound to HLA-DR3. Nature 378, 457–462 (1995).
Oh, D. Y. & Bang, Y. J. HER2-targeted therapies—a role beyond breast cancer. Nat. Rev. Clin. Oncol. 17, 33–48 (2020).
Sulzer, D. et al. Erratum: T cells from patients with Parkinson’s disease recognize α-synuclein peptides. Nature 549, 292 (2017).
Kim, C. Y., Quarsten, H., Bergseng, E., Khosla, C. & Sollid, L. M. Structural basis for HLA-DQ2-mediated presentation of gluten epitopes in celiac disease. Proc. Natl Acad. Sci. USA 101, 4175–4179 (2004).
Nguyen, T. B. et al. Unraveling the structural basis for the unusually rich association of human leukocyte antigen DQ2.5 with class-II-associated invariant chain peptides. J. Biol. Chem. 292, 9218–9228 (2017).
Kassardjian, A. et al. Modular adjuvant-free pan-HLA-DR-immunotargeting subunit vaccine against SARS-CoV-2 elicits broad sarbecovirus-neutralizing antibody responses. Cell Rep. 42, 112391 (2023).
Jensen, K. K. et al. Improved methods for predicting peptide binding affinity to MHC class II molecules. Immunology 154, 394–406 (2018).
Mirdita, M. et al. ColabFold: making protein folding accessible to all. Nat. Methods 19, 679–682 (2022).
Van Deventer, J. A. & Wittrup, K. D. Yeast surface display for antibody isolation: library construction, library screening, and affinity maturation. Methods Mol. Biol. 1131, 151–181 (2014).
Chen, S. W. et al. Analysis of SPR signal by using optimized Savitzky–Golay filter. Spectrosc. Spect. Anal. 35, 1124–1128 (2015).
Steinle, A. & Schendel, D. J. HLA class I alleles of LCL 721 and 174 × CEM.T2 (T2). Tissue Antigens 44, 268–270 (1994).
Jiang, W. et al. pH-susceptibility of HLA-DO tunes DO/DM ratios to regulate HLA-DM catalytic activity. Sci. Rep. 5, 17333 (2015).
Busch, R., Doebele, R. C., Patil, N. S., Pashine, A. & Mellins, E. D. Accessory molecules for MHC class II peptide loading. Curr. Opin. Immunol. 12, 99–106 (2000).
Alvaro-Benito, M., Wieczorek, M., Sticht, J., Kipar, C. & Freund, C. HLA-DMA polymorphisms differentially affect MHC class II peptide loading. J. Immunol. 194, 803–816 (2015).
Punjani, A., Rubinstein, J. L., Fleet, D. J. & Brubaker, M. A. cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination. Nat. Methods 14, 290–296 (2017).
Sanchez-Garcia, R. et al. DeepEMhancer: a deep learning solution for cryo-EM volume post-processing. Commun. Biol. 4, 874 (2021).
Goddard, T. D. et al. UCSF ChimeraX: meeting modern challenges in visualization and analysis. Protein Sci. 27, 14–25 (2018).
Pettersen, E. F. et al. UCSF ChimeraX: structure visualization for researchers, educators, and developers. Protein Sci. 30, 70–82 (2021).
Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development of Coot. Acta Crystallogr. D 66, 486–501 (2010).
Liebschner, D. et al. Macromolecular structure determination using X-rays, neutrons and electrons: recent developments in Phenix. Acta Crystallogr. D 75, 861–877 (2019).
Echols, N. et al. Graphical tools for macromolecular crystallography in PHENIX. J. Appl. Crystallogr. 45, 581–586 (2012).
Chen, V. B. et al. MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr. D 66, 12–21 (2010).
Morin, A. et al. Collaboration gets the most out of software. eLife 2, e01456 (2013).
Jude, K. M. et al Engineered peptide-specific binder in complex with HLA-DR1/CLIP. Worldwide Protein Data Bank https://doi.org/10.2210/pdb8vsj/pdb (2024).
